AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 302 min read$CNTB

Connect Biopharma Stock Rises 25% After Positive Phase 2 COPD Trial Results

Connect Biopharma (CNTB) shares rose 24.57% to $1.2350 after reporting positive Phase 2 trial results for rademikibart in COPD patients, showing significant reductions in treatment failure and exacerbations. The stock's volume surged to 149.92 million shares. The company plans to discuss a potential Phase 3 program with the FDA.

Original reporting
rttnews.com
Published Sep 30, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 6:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CNTB
Bullish
high confidence
Mentioned
$CNTB
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CNTBBullishHigh
01

Why it matters

The trial showed an 81% reduction in treatment failure and up to 100% reduction in emergency visits, prompting a 24.6% intraday price surge and plans to discuss a Phase 3 program with the FDA.

02

Market read

The announcement provides fresh, material data for a small‑cap biotech, creating a clear short‑term trading opportunity.

03

What to watch

Regulatory timeline uncertainty and the need for larger Phase 3 enrollment may temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Connect Biopharma (CNTB) is a Nasdaq‑listed biotech focused on respiratory therapies. The Seabreeze STAT COPD study evaluated rademikibart as an add‑on treatment.

Company-level read

Ticker impact

$CNTBBullishHigh confidence
Context

Connect Biopharma announced positive Phase 2 COPD trial results, driving a 24.6% share jump.

Expected impact

upward pressure as the market prices in the favorable efficacy data.

Evidence & confidence

Phase 2 data showing large reductions in treatment failure and exacerbations is material for a biotech and has moved the stock sharply on the day of release.

Market effects

Sector

Boosts sentiment for the broader COPD/respiratory biotech space.

Regional

Positive for US-listed biotech stocks trading on Nasdaq.

Global

Limited to investors tracking clinical‑trial pipelines; no immediate macro effect.

Counterpoint

What could challenge this read

If the Phase 3 data fails to replicate, the rally could reverse sharply.

Key entities

  • company
    Connect Biopharma Holdings Limited

    Nasdaq‑listed biotech reporting Phase 2 COPD data.

  • drug
    rademikibart

    Investigational therapy evaluated in the COPD trial.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 30
$CNTBHighAI 9/10

Why is Connect Biopharma stock surging today?

Connect Biopharma (CNTB) stock rose 17.4% to $1.165 after positive Phase 2 trial results for its COPD treatment, rademikibart. The drug showed significant efficacy, reducing treatment failure rates and exacerbations. BTIG lowered its price target to $5.00 but maintained a Buy rating. Analysts generally remain positive, with a consensus price target of $6.14. The company plans to discuss Phase 3 development with the FDA. The broader market also gained due to softer inflation data.

investing.com2 min
SEP 30
$CNTBHighAI 8/10

BTIG cuts Connect Biopharma stock price target on trial timeline

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.

investing.com2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma stock jumps on positive COPD trial data

Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.

investing.com2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in…

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation – Rademikibart significantly reduced the rate of treatment failure c

SEC EDGAR 8-K2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma (CNTB) reported positive Phase 2 data for rademikibart, showing an 81% reduction in treatment failure and 85% fewer new COPD exacerbations vs. placebo. The drug also eliminated hospitalizations/ED visits. The company plans to discuss the results with the FDA and host a conference call today.

globenewswire.com2 min